Obesity is a chronic metabolic disease characterized by excessive body fat accumulation resulting from sustained positive energy balance, in which regulatory systems involving leptin, ghrelin, and insulin fail to restore homeostasis. Expanded, dysfunctional adipose tissue develops chronic low-grade inflammation and altered adipokine secretion, while hypothalamic dysregulation and leptin resistance perpetuate excess intake. Genetic susceptibility (FTO, MC4R, LEP, LEPR) interacts with environmental and behavioral factors, and the resulting state drives insulin resistance, dyslipidemia, hypertension, and other cardiometabolic complications.
Ask a research question about Obesity. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Obesity
creation_date: '2025-12-18T17:01:35Z'
description: >-
Obesity is a chronic metabolic disease characterized by excessive body fat
accumulation resulting from sustained positive energy balance, in which
regulatory systems involving leptin, ghrelin, and insulin fail to restore
homeostasis. Expanded, dysfunctional adipose tissue develops chronic
low-grade inflammation and altered adipokine secretion, while hypothalamic
dysregulation and leptin resistance perpetuate excess intake. Genetic
susceptibility (FTO, MC4R, LEP, LEPR) interacts with environmental and
behavioral factors, and the resulting state drives insulin resistance,
dyslipidemia, hypertension, and other cardiometabolic complications.
category: Complex
parents:
- Metabolic Disease
disease_term:
preferred_term: obesity disorder
term:
id: MONDO:0011122
label: obesity disorder
pathophysiology:
- name: Energy Imbalance
description: >
Chronic positive energy balance from excess caloric intake relative
to expenditure leads to fat accumulation. Multiple regulatory systems
(leptin, ghrelin, insulin) fail to restore balance.
biological_processes:
- preferred_term: Energy Homeostasis
term:
id: GO:0097009
label: energy homeostasis
evidence:
- reference: PMID:17212793
reference_title: "The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review."
supports: SUPPORT
snippet: "Leptin is a mediator of long-term regulation of energy balance, suppressing food intake and thereby inducing weight loss. Ghrelin on the other hand is a fast-acting hormone, seemingly playing a role in meal initiation."
explanation: Describes the role of leptin and ghrelin as key hormones regulating energy balance in obesity.
- reference: PMID:17212793
reference_title: "The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review."
supports: SUPPORT
snippet: "In obese subjects the circulating level of the anorexigenic hormone leptin is increased, whereas surprisingly, the level of the orexigenic hormone ghrelin is decreased. It is now established that obese patients are leptin-resistant."
explanation: Explains the paradox of elevated leptin levels in obesity with concurrent leptin resistance, contributing to failed energy balance restoration.
- name: Adipose Tissue Dysfunction
description: >
Expanded adipose tissue becomes dysfunctional with increased inflammation,
altered adipokine secretion, and impaired metabolic function. Adipocyte
hypertrophy leads to hypoxia and macrophage infiltration.
cell_types:
- preferred_term: Adipocyte
term:
id: CL:0000136
label: adipocyte
- preferred_term: Adipose Tissue Macrophage
term:
id: CL:0000863
label: M1 macrophage
biological_processes:
- preferred_term: Adipokine Secretion
term:
id: GO:0070163
label: regulation of adiponectin secretion
evidence:
- reference: PMID:39456156
reference_title: "Adipose Tissue Plasticity: A Comprehensive Definition and Multidimensional Insight."
supports: SUPPORT
snippet: "Under various physiological or pathological conditions, adipose tissue shifts cellular composition, lipid storage, and organelle dynamics to respond to the stress; this remodeling is called \"adipose tissue plasticity\"."
explanation: Describes the dynamic remodeling of adipose tissue in response to obesity, including changes in cellular composition and metabolic function.
- reference: PMID:14679177
reference_title: "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance."
supports: SUPPORT
snippet: "Histologically, there is evidence of significant infiltration of macrophages, but not neutrophils and lymphocytes, into WAT of obese mice, with signs of adipocyte lipolysis and formation of multinucleate giant cells."
explanation: Provides histological evidence of macrophage infiltration into dysfunctional adipose tissue in obesity.
- reference: PMID:14679177
reference_title: "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance."
supports: SUPPORT
snippet: "These data suggest that macrophages in WAT play an active role in morbid obesity and that macrophage-related inflammatory activities may contribute to the pathogenesis of obesity-induced insulin resistance."
explanation: Establishes the causal role of adipose tissue macrophages in obesity-related metabolic dysfunction.
- name: Chronic Low-Grade Inflammation
description: >
Systemic inflammation from adipose tissue contributes to insulin
resistance, cardiovascular disease, and other complications. Elevated
CRP, IL-6, and TNF-alpha levels.
biological_processes:
- preferred_term: Inflammatory Response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:14679177
reference_title: "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance."
supports: SUPPORT
snippet: "Increasing evidence from human population studies and animal research has established correlative as well as causative links between chronic inflammation and insulin resistance."
explanation: Establishes both correlative and causative links between chronic inflammation and insulin resistance in obesity.
- reference: PMID:14679177
reference_title: "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance."
supports: SUPPORT
snippet: "We propose that obesity-related insulin resistance is, at least in part, a chronic inflammatory disease initiated in adipose tissue."
explanation: Proposes that obesity-induced insulin resistance represents a chronic inflammatory disease originating in adipose tissue.
- reference: PMID:27503945
reference_title: "Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance?"
supports: SUPPORT
snippet: "Particularly chronic inflammation in adipose tissue seems to play an important role in the development of obesity-related insulin resistance."
explanation: Highlights the central role of chronic adipose tissue inflammation in obesity-related insulin resistance.
- name: Hypothalamic Dysregulation
description: >
Central appetite regulation becomes impaired with leptin resistance
and altered reward signaling, perpetuating overeating despite adequate
energy stores. Hypothalamic neuroinflammation involves microglial and
astrocyte activation that impairs melanocortin signaling.
cell_types:
- preferred_term: Hypothalamus Cell
term:
id: CL:2000030
label: hypothalamus cell
- preferred_term: Microglial Cell
term:
id: CL:0000129
label: microglial cell
biological_processes:
- preferred_term: Feeding Behavior
term:
id: GO:0007631
label: feeding behavior
evidence:
- reference: PMID:38490517
reference_title: "Novel mechanisms involved in leptin sensitization in obesity."
supports: SUPPORT
snippet: "Leptin acts through its receptor LepRb, expressed mainly in the hypothalamus, and induces a negative energy balance by potent inhibition of feeding and activation of energy expenditure."
explanation: Describes the central hypothalamic mechanism by which leptin normally regulates energy balance.
- reference: PMID:38490517
reference_title: "Novel mechanisms involved in leptin sensitization in obesity."
supports: SUPPORT
snippet: "However, the majority of patients with obesity presents elevated leptin production, suggesting that in this setting leptin is ineffective in the regulation of energy balance."
explanation: Explains leptin resistance in obesity where elevated leptin fails to regulate energy balance through hypothalamic circuits.
- name: Adipocyte Mitochondrial Dysfunction
description: >
Obesity causes mitochondrial fragmentation in white adipocytes through
RalA-mediated activation of the fission protein DRP1 (DNM1L). This leads
to reduced oxidative capacity and contributes to weight gain and insulin
resistance. Mitochondrial dynamics shift toward excessive fission.
cell_types:
- preferred_term: Adipocyte
term:
id: CL:0000136
label: adipocyte
biological_processes:
- preferred_term: Mitochondrial Fission
term:
id: GO:0000266
label: mitochondrial fission
- preferred_term: Fatty Acid Oxidation
term:
id: GO:0019395
label: fatty acid oxidation
evidence:
- reference: PMID:38286821
reference_title: "Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation."
supports: SUPPORT
snippet: "Here we show that high-fat diet (HFD) feeding causes mitochondrial fragmentation in inguinal white adipocytes from male mice, leading to reduced oxidative capacity by a process dependent on the small GTPase RalA."
explanation: Demonstrates that obesity causes mitochondrial fragmentation through RalA in white adipocytes.
- reference: PMID:38286821
reference_title: "Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation."
supports: SUPPORT
snippet: "Mechanistically, RalA increases fission in adipocytes by reversing the inhibitory Ser637 phosphorylation of the fission protein Drp1, leading to more mitochondrial fragmentation."
explanation: Describes the molecular mechanism by which RalA promotes mitochondrial fission through DRP1 dephosphorylation.
- reference: PMID:38286821
reference_title: "Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation."
supports: SUPPORT
snippet: "Adipose tissue expression of the human homolog of Drp1, DNM1L, is positively correlated with obesity and insulin resistance."
explanation: Provides human evidence linking DNM1L expression to obesity and insulin resistance.
mechanistic_hypotheses:
- hypothesis_group_id: pgs_context_amplification
hypothesis_label: Amplification of polygenic obesity risk in adverse contexts
via shared energy-imbalance convergence
status: EMERGING
description: >-
Polygenic-score-by-context (PGS×C) interactions reported for obesity in the
UK Biobank appear to reflect amplification rather than context-specific
causal variants: the same susceptibility loci (e.g. FTO, MC4R, and other
appetite/CNS-acting variants) exert systematically larger effects in
disease-promoting contexts. This entry proposes that the amplification arises
because polygenic liability and adverse exposures — obesogenic diet, physical
inactivity, alcohol intake and socioeconomic deprivation — converge on the
shared Energy Imbalance node, so their joint effect on the liability-threshold
scale is super-additive rather than additive. Nagpal & Gibson (Nat Genet
2026, PMID:42443528) show amplifying context pairs for BMI-defined obesity
(e.g. glucose with omega-3 fatty acids, and walking pace with beer intake)
and note that the major contexts differ between BMI- and waist-to-hip-ratio
definitions, consistent with BMI polymorphisms acting on central appetite
regulation versus WHR variants acting on peripheral metabolic traits.
evidence:
- reference: PMID:42443528
reference_title: "Pervasive interactions between exposures and polygenic risk can inform more effective clinical and behavioral interventions."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: The predominant mechanism for PGS×C is the amplification of genetic
effects in adverse contexts, such as low polyunsaturated fatty acids or social
determinants of ill health
explanation: >-
Direct source (Nagpal & Gibson 2026): across seven UK Biobank diseases and
75 contexts, amplification of genetic effects in adverse contexts is
identified as the predominant mechanism of PGS×context interaction — the
mechanism applied in this hypothesis.
- reference: PMID:37228747
reference_title: "Amplification is the primary mode of gene-by-sex interaction in complex human traits."
supports: SUPPORT
evidence_source: COMPUTATIONAL
snippet: GxSex is pervasive but acts primarily through systematic sex differences
in the magnitude of many genetic effects
explanation: >-
Corroborates amplification — systematic differences in the magnitude of
polygenic effects rather than in the identity of causal variants — as the
primary mode of gene-by-context interaction.
notes: >-
EMERGING hypothesis motivated by population-scale PGS×context analyses
(primary source PMID:42443528; general amplification mechanism corroborated
by PMID:37228747). The convergence claim (polygenic liability + adverse
exposures → Energy Imbalance) is a mechanistic interpretation and is not
itself established as causal — see the reverse-causation knowledge gap under
discussions.
phenotypes:
- name: Increased Body Mass Index
category: Metabolic
frequency: VERY_FREQUENT
diagnostic: true
notes: BMI greater than or equal to 30 kg/m2
phenotype_term:
preferred_term: Obesity
term:
id: HP:0001513
label: Obesity
- name: Insulin Resistance
category: Metabolic
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Insulin Resistance
term:
id: HP:0000855
label: Insulin resistance
evidence:
- reference: PMID:14679177
reference_title: "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance."
supports: SUPPORT
snippet: "Insulin resistance arises from the inability of insulin to act normally in regulating nutrient metabolism in peripheral tissues."
explanation: Defines insulin resistance as a key metabolic phenotype in obesity.
- reference: PMID:27503945
reference_title: "Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance?"
supports: SUPPORT
snippet: "Insulin resistance may link accumulation of adipose tissue in obesity to metabolic diseases, although the underlying mechanisms are not completely understood."
explanation: Links adipose tissue accumulation in obesity to insulin resistance and metabolic disease.
- name: Dyslipidemia
category: Metabolic
frequency: FREQUENT
phenotype_term:
preferred_term: Dyslipidemia
term:
id: HP:0003077
label: Hyperlipidemia
- name: Hypertension
category: Cardiovascular
frequency: FREQUENT
phenotype_term:
preferred_term: Hypertension
term:
id: HP:0000822
label: Hypertension
evidence:
- reference: PMID:19320986
reference_title: "The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Statistically significant associations with obesity were found with the incidence of type II diabetes, all cancers except esophageal and prostate cancer, all cardiovascular diseases, asthma, gallbladder disease, osteoarthritis and chronic back pain."
explanation: Systematic review and meta-analysis linking obesity to incident cardiovascular disease, supporting hypertension as an obesity-related complication.
- name: Obstructive Sleep Apnea
category: Respiratory
frequency: FREQUENT
phenotype_term:
preferred_term: Sleep Apnea
term:
id: HP:0010535
label: Sleep apnea
- name: Joint Pain
category: Musculoskeletal
frequency: FREQUENT
notes: Weight-bearing joint stress
phenotype_term:
preferred_term: Arthralgia
term:
id: HP:0002829
label: Arthralgia
evidence:
- reference: PMID:19320986
reference_title: "The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The meta-analysis determined statistically significant associations for overweight with the incidence of type II diabetes, all cancers except esophageal (female), pancreatic and prostate cancer, all cardiovascular diseases (except congestive heart failure), asthma, gallbladder disease, osteoarthritis and chronic back pain."
explanation: Meta-analysis linking excess weight to incident osteoarthritis and chronic back pain, supporting joint pain as an obesity-related musculoskeletal complication.
- name: Fatigue
category: Systemic
frequency: FREQUENT
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
biochemical:
- name: Leptin
presence: Elevated
context: Leptin resistance present despite high levels
- name: Adiponectin
presence: Decreased
context: Reduced with adipose dysfunction
- name: C-Reactive Protein
presence: Elevated
context: Chronic inflammation marker
- name: Fasting Insulin
presence: Elevated
context: Compensatory hyperinsulinemia
genetic:
- name: FTO
gene_term:
preferred_term: FTO
term:
id: hgnc:24678
label: FTO
association: Risk Factor
notes: Strongest common variant association
evidence:
- reference: PMID:17434869
reference_title: "A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The 16% of adults who are homozygous for the risk allele weighed about 3 kilograms more and had 1.67-fold increased odds of obesity when compared with those not inheriting a risk allele."
explanation: Large genome-wide association study establishing the common FTO variant as a robust risk factor for higher BMI and obesity.
- name: MC4R
gene_term:
preferred_term: MC4R
term:
id: hgnc:6932
label: MC4R
association: Risk Factor
notes: Appetite regulation
- name: LEP
gene_term:
preferred_term: LEP
term:
id: hgnc:6553
label: LEP
association: Causative
notes: Rare congenital leptin deficiency
evidence:
- reference: PMID:9202122
reference_title: "Congenital leptin deficiency is associated with severe early-onset obesity in humans."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The severe obesity found in these congenitally leptin-deficient subjects provides the first genetic evidence that leptin is an important regulator of energy balance in humans."
explanation: First human evidence that a homozygous LEP frameshift mutation causes severe early-onset obesity via leptin deficiency.
- name: LEPR
gene_term:
preferred_term: LEPR
term:
id: hgnc:6554
label: LEPR
association: Causative
notes: Rare leptin receptor deficiency
- name: POMC
gene_term:
preferred_term: POMC
term:
id: hgnc:9201
label: POMC
association: Causative
notes: Rare, causes severe early-onset obesity
environmental:
- name: High-Calorie Diet
exposure_term:
preferred_term: high-calorie dietary pattern
modifier: INCREASED
term:
id: XCO:0000013
label: diet
notes: Especially ultra-processed foods
evidence:
- reference: PMID:31105044
reference_title: "Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "participants gaining 0.9 ± 0.3 kg (p = 0.009) during the ultra-processed diet and losing 0.9 ± 0.3 kg (p = 0.007) during the unprocessed diet"
explanation: "Inpatient randomized crossover trial with diets matched for presented calories, energy density, macronutrients, sugar, sodium and fibre -- so the 508 kcal/day excess intake and the weight change are attributable to processing itself rather than to nutrient composition. This is the strongest available design for the annotation claim."
- name: Sedentary Lifestyle
exposure_term:
preferred_term: sedentary lifestyle
term:
id: ECTO:6000004
label: exposure to sedentary lifestyle
notes: Sedentary behaviour is associated with becoming overweight or obese (OR 1.33
highest vs lowest category), though its association with body weight itself is
small and inconsistent
evidence:
- reference: PMID:29189928
reference_title: "Sedentary Behavior and Body Weight and Composition in Adults: A Systematic Review and Meta-analysis of Prospective Studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Meta-analysis of data from prospective cohort studies showed small, inconsistent and non-significant associations between sedentary behavior and body weight"
explanation: "PARTIAL, and the note was rewritten, because this is less settled than it is usually assumed to be. The same meta-analysis did find a significant odds ratio of 1.33 for becoming overweight or obese in the highest versus lowest sedentary category, and a small waist-circumference effect -- but not an association with body weight, and it does not evidence the reduced-energy-expenditure mechanism the note previously asserted."
- reference: PMID:29189928
reference_title: "Sedentary Behavior and Body Weight and Composition in Adults: A Systematic Review and Meta-analysis of Prospective Studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The odds ratio of becoming overweight or obese was 1.33 (95% CI 1.11-1.60; p = 0.001) in the highest compared with lowest categories of sedentary behavior"
explanation: "Quotes the odds ratio the rewritten note states, so the note is self-supporting rather than relying on a figure the reader must go to the abstract to find. Paired deliberately with the PARTIAL item above: this is the positive signal, that one is the null result it sits inside."
- name: Obesogenic Environment
notes: Food availability, marketing, built environment
evidence:
- reference: PMID:35290815
reference_title: "The impact of the consumer and neighbourhood food environment on dietary intake and obesity-related outcomes: A systematic review of causal impact studies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the number of and distance to unhealthy food outlets increased the likelihood of fast-food consumption and higher BMI for children of any SES"
explanation: "Systematic review restricted to causal-inference studies. PARTIAL on two counts: the BMI effect is established for children of any socioeconomic status but among adults only for selected groups (females, black and Hispanic residents of low and medium density areas), and the marketing component of this annotation is not covered."
- name: Sleep Deprivation
exposure_term:
preferred_term: sleep deprivation
term:
id: XCO:0001069
label: sleep restriction
notes: Alters appetite hormones
evidence:
- reference: PMID:15602591
reference_title: "Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In Western societies, where chronic sleep restriction is common and food is widely available, changes in appetite regulatory hormones with sleep curtailment may contribute to obesity."
explanation: Population cohort study showing short sleep duration reduces leptin and elevates ghrelin, linking sleep deprivation to increased BMI and obesity risk.
- name: Psychological Stress
exposure_term:
preferred_term: psychological stress
term:
id: XCO:0001265
label: stress
notes: Emotional eating
evidence:
- reference: PMID:19926299
reference_title: "Stress-induced obesity and the emotional nervous system."
supports: SUPPORT
evidence_source: OTHER
snippet: "Stress and emotional brain networks foster eating behaviors that can lead to obesity"
explanation: "States the emotional-eating route this annotation names, and gives the mechanism: stressors bias cognition toward emotional activity and degraded executive function, favouring habitual over deliberate food choice. OTHER because the quoted sentence is a review's mechanistic synthesis rather than a measurement."
treatments:
- name: Lifestyle Modification
description: Dietary changes and increased physical activity as foundation of treatment.
treatment_term:
preferred_term: Lifestyle Therapy
term:
id: NCIT:C15900
label: Lifestyle Therapy
evidence:
- reference: PMID:25182101
reference_title: "Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Significant weight loss was observed with any low-carbohydrate or low-fat diet."
explanation: Meta-analysis of randomized trials showing dietary lifestyle modification produces significant weight loss in overweight and obese adults.
- name: GLP-1 Receptor Agonists
description: Semaglutide, liraglutide provide substantial weight loss through central appetite suppression and metabolic effects.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
evidence:
- reference: PMID:33567185
reference_title: "Once-Weekly Semaglutide in Adults with Overweight or Obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight."
explanation: STEP 1 randomized trial demonstrating substantial, sustained weight loss with the GLP-1 receptor agonist semaglutide in obesity.
- reference: PMID:41782434
reference_title: "Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach."
supports: SUPPORT
evidence_source: OTHER
snippet: "Strong recommendations were made for bupropion-naltrexone, semaglutide, tirzepatide, and setmelanotide, with moderate-certainty evidence."
explanation: The joint TOS/OMA/OAC pharmacological-management guidance makes a strong recommendation for semaglutide (a GLP-1 receptor agonist) for adults with obesity.
- name: GLP-1/GIP Dual Agonists
description: Tirzepatide offers enhanced weight loss of 15-25% through dual incretin receptor activation.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
evidence:
- reference: PMID:35658024
reference_title: "Tirzepatide Once Weekly for the Treatment of Obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight."
explanation: SURMOUNT-1 randomized trial showing the GLP-1/GIP dual agonist tirzepatide produces substantial, sustained weight loss in obesity.
- reference: PMID:41782434
reference_title: "Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach."
supports: SUPPORT
evidence_source: OTHER
snippet: "Strong recommendations were made for bupropion-naltrexone, semaglutide, tirzepatide, and setmelanotide, with moderate-certainty evidence."
explanation: The joint TOS/OMA/OAC pharmacological-management guidance makes a strong recommendation for tirzepatide (a GLP-1/GIP dual agonist) for adults with obesity.
- name: Bariatric Surgery
therapeutic_modality: SURGERY
description: Roux-en-Y gastric bypass, sleeve gastrectomy for severe obesity.
treatment_term:
preferred_term: surgical procedure
term:
id: NCIT:C15329
label: Surgical Procedure
evidence:
- reference: PMID:15616203
reference_title: "Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "As compared with conventional therapy, bariatric surgery appears to be a viable option for the treatment of severe obesity, resulting in long-term weight loss, improved lifestyle, and, except for hypercholesterolemia, amelioration in risk factors that were elevated at baseline."
explanation: Swedish Obese Subjects study showing bariatric surgery produces durable weight loss and risk-factor improvement in severe obesity.
- name: Behavioral Therapy
therapeutic_modality: BEHAVIORAL
description: Cognitive behavioral therapy for eating behaviors.
treatment_term:
preferred_term: behavioral counseling
term:
id: NCIT:C181743
label: Behavioral Counseling
- name: Orlistat
description: Lipase inhibitor reducing fat absorption.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: orlistat
term:
id: CHEBI:94686
label: orlistat
evidence:
- reference: PMID:9683204
reference_title: "Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period."
explanation: European Multicentre Orlistat randomized trial demonstrating the lipase inhibitor orlistat produces clinically significant weight loss in obese patients.
discussions:
- discussion_id: obesity_pgsxc_reverse_causation
prompt: >-
Are the obesity PGS×context interactions driven by adverse exposures causally
amplifying genetic risk, or are some "contexts" (e.g. fasting insulin, leptin,
reduced physical activity) actually downstream consequences of adiposity
(reverse causation)?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Energy Imbalance
- biochemical#Leptin
- biochemical#Fasting Insulin
- environmental#Sedentary Lifestyle
rationale: >-
Population PGS×context analyses (Nagpal & Gibson 2026, PMID:42443528) are
largely unable to establish the causality of specific contexts. For obesity
this is acute for the biochemical "contexts": leptin and fasting insulin rise
as a consequence of increased fat mass and are modelled in this entry as
readouts of adipose dysfunction rather than upstream drivers, and reduced
physical activity or slower walking pace may be consequences of established
obesity rather than causes. Distinguishing genuine amplification of genetic
effects from reverse causation determines whether the modelled lifestyle
interventions would actually reduce risk.
proposed_experiments:
- experiment_id: obesity_pgsxc_mr_direction
name: Mendelian randomization of exposure-to-obesity direction across PGS strata
description: >-
Use bidirectional / multivariable Mendelian randomization to test whether
each candidate context (physical activity, alcohol, fasting insulin, leptin)
causally affects adiposity versus being a consequence of it, and whether the
causal effect estimate scales with polygenic liability as the amplification
model predicts.
decision_criterion: >-
A context is retained as a causal amplifier if MR supports
exposure-to-disease directionality and the exposure-attributable risk
difference increases across increasing PGS strata; it is flagged as a
reverse-causation suspect otherwise.
- experiment_id: obesity_pgsxc_prospective_temporal
name: Prospective incident-obesity analysis restricted to pre-onset exposure
windows
description: >-
Restrict exposures to measurements taken well before obesity onset and
repeat the PGS×context liability-threshold modelling on incident cases only,
to reduce the chance that exposure values (particularly activity and
metabolic biomarkers) reflect established adiposity rather than antecedent
risk.
decision_criterion: >-
Amplification is supported if the PGS×context deviation from additivity
persists when only pre-onset exposure windows and incident cases are used.
datasets:
# Obesity Gut Microbiome Studies
- accession: bioproject:PRJNA290729
title: Gut microbiome in obesity after weight-loss intervention
description: >-
Whole metagenome shotgun sequencing characterizing gut microbial community
of obese patients following weight-loss intervention. Tracks microbiome
changes with weight loss.
organism:
preferred_term: human gut metagenome
term:
id: NCBITaxon:408170
label: human gut metagenome
data_type: WGS
sample_types:
- preferred_term: fecal sample
term:
id: UBERON:0001988
label: feces
tissue_term:
preferred_term: feces
term:
id: UBERON:0001988
label: feces
conditions:
- obese pre-intervention
- obese post-weight loss
publication: PMID:26934690
notes: PLOS ONE 2016 - weight loss microbiome dynamics
- accession: bioproject:PRJNA328258
title: Gut microbiome in pediatric NAFLD and obesity
description: >-
Shotgun metagenomics examining taxonomic and functional differences
between microbiomes of youth with obesity with and without non-alcoholic
fatty liver disease (NAFLD).
organism:
preferred_term: human gut metagenome
term:
id: NCBITaxon:408170
label: human gut metagenome
data_type: WGS
sample_types:
- preferred_term: fecal sample
term:
id: UBERON:0001988
label: feces
tissue_term:
preferred_term: feces
term:
id: UBERON:0001988
label: feces
sample_count: 36
conditions:
- obese with NAFLD
- obese without NAFLD
- healthy controls
publication: PMID:35344283
notes: Hepatology Communications 2022
- accession: bioproject:PRJNA881023
title: Gut microbiome of metabolically healthy obese individuals
description: >-
Metagenomic characterization of gut microbiome in metabolically healthy
obese (MHO) patients and correlations with metabolic and inflammatory
profiles. 120 obese individuals without metabolic comorbidities.
organism:
preferred_term: human gut metagenome
term:
id: NCBITaxon:408170
label: human gut metagenome
data_type: WGS
sample_types:
- preferred_term: fecal sample
term:
id: UBERON:0001988
label: feces
tissue_term:
preferred_term: feces
term:
id: UBERON:0001988
label: feces
sample_count: 120
conditions:
- metabolically healthy obese
notes: Scientific Reports 2024 - MHO microbiome signatures
- accession: bioproject:PRJNA417579
title: Clostridia diversity and obesity association
description: >-
High-resolution analysis of intra-species diversity in gut microbiome
focusing on Clostridia class associations with obesity. 16S rRNA, dnaK,
and gyrB gene sequencing.
organism:
preferred_term: human gut metagenome
term:
id: NCBITaxon:408170
label: human gut metagenome
sample_types:
- preferred_term: fecal sample
term:
id: UBERON:0001988
label: feces
tissue_term:
preferred_term: feces
term:
id: UBERON:0001988
label: feces
conditions:
- obese individuals
- lean controls
notes: mSystems 2024 - Clostridia negatively associated with obesity
references:
- reference: DOI:10.3390/biom14101223
title: 'Adipose Tissue Plasticity: A Comprehensive Definition and Multidimensional Insight'
findings: []
- reference: DOI:10.3390/cimb47050343
title: Key Roles of Brown, Subcutaneous, and Visceral Adipose Tissues in Obesity and Insulin Resistance
findings: []
- reference: DOI:10.3390/diagnostics15121482
title: 'Unraveling the Genetic Architecture of Obesity: A Path to Personalized Medicine'
findings: []
- reference: DOI:10.3390/ijms25126681
title: 'Adipocyte Mitochondria: Deciphering Energetic Functions across Fat Depots in Obesity and Type 2 Diabetes'
findings: []
- reference: DOI:10.3390/ijms25158202
title: Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
findings: []
- reference: DOI:10.3390/medicines12030019
title: 'Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies'
findings: []
Pathophysiology description Obesity emerges from sustained positive energy balance acting on genetically and epigenetically susceptible neuroendocrine and peripheral tissues. A unifying sequence begins with subcutaneous adipocyte hypertrophy and limited hyperplasia, provoking local hypoxia, macrophage infiltration, and pro‑fibrotic extracellular matrix remodeling. This immunometabolic state (“metaflammation”) is sustained by adipokines and cytokines (↑leptin, resistin, TNF, IL‑6; ↓adiponectin), and is compounded by mitochondrial dysfunction, including pathological mitochondrial fission in white adipocytes driven by the small GTPase RalA and DRP1/DNM1L, which reduces oxidative capacity and promotes systemic insulin resistance and ectopic lipid deposition (liver/muscle) (das2024adipocytemitochondriadeciphering pages 14-16, dobre2025keyrolesof pages 11-13, mo2024adiposetissueplasticity pages 17-18).
Concurrently, hypothalamic neuroinflammation disrupts leptin and insulin signaling in appetite/energy‑balance circuits. Microglia and astrocytes participate in neuronal–glial crosstalk that impairs melanocortin signaling (POMC→α‑MSH→MC4R) and favors orexigenic NPY/AgRP activity, contributing to hyperphagia and reduced energy expenditure (kunnathodi2025unravelingthegenetic pages 4-6, kunnathodi2025unravelingthegenetic pages 3-4). Organ crosstalk propagates disease: adipose‑derived FFAs, cytokines, and extracellular vesicles alter hepatic and muscle insulin action and promote metabolic dysfunction‑associated steatotic liver disease (MASLD); hepatokines (e.g., FGF21) and batokines (e.g., NRG4) further influence systemic metabolism (dobre2025keyrolesof pages 11-13, ullah2025obesityclinicalimpact pages 15-17).
The gut microbiome modulates host metabolism via short‑chain fatty acids (SCFAs), bile acids (BAs), and endotoxin. Dysbiosis shifts SCFA/BA pools and impairs barrier integrity, increasing LPS translocation and TLR4‑NF‑κB signaling, thereby amplifying adipose and hypothalamic inflammation and insulin resistance (das2024adipocytemitochondriadeciphering pages 14-16, ullah2025obesityclinicalimpact pages 15-17). Thermogenic adipose (brown and beige) normally dissipates energy via UCP1‑mediated mitochondrial uncoupling under sympathetic/β3‑adrenergic control; in obesity, impaired browning/thermogenesis lowers energy expenditure, while targeted activation promises therapeutic benefit but with safety and inter‑individual variability considerations (sitarUnknownyearbrownandbeige pages 5-6, mo2024adiposetissueplasticity pages 17-18, das2024adipocytemitochondriadeciphering pages 14-16).
Genetically, obesity includes rare monogenic forms (e.g., LEP, LEPR, POMC, MC4R) that principally disrupt hypothalamic circuits and common polygenic obesity wherein hundreds to thousands of loci—often brain‑expressed (e.g., FTO, ADCY3)—modulate appetite and energy expenditure; epigenetic marks further integrate environmental exposures with metabolic phenotypes (kunnathodi2025unravelingthegenetic pages 4-6, kunnathodi2025unravelingthegenetic pages 3-4).
Recent developments and applications (2023–2024) - Mitochondrial dynamics: Nature Metabolism (2024) identified RalA‑dependent activation of DRP1 (DNM1L) in WAT as a causal mechanism for mitochondrial fragmentation and reduced oxidative capacity, linking adipocyte mitochondrial fission directly to weight gain and insulin resistance (das2024adipocytemitochondriadeciphering pages 14-16). - Hypothalamic neuroglia: Neuronal–glial mechanisms in hypothalamic inflammation affecting leptin/insulin sensitivity and energy homeostasis were synthesized in 2024, highlighting glia as therapeutic targets (kunnathodi2025unravelingthegenetic pages 4-6). - Incretin biology and pharmacology: GLP‑1 physiology in obesity and the mechanistic basis for GLP‑1 and dual GIP/GLP‑1 agonists were updated in 2024; these agents reduce food intake via central pathways, delay gastric emptying, enhance glucose‑dependent insulin secretion, and may improve adipose/liver inflammation, explaining 15–25% mean weight loss and metabolic benefits in trials (ullah2025obesityclinicalimpact pages 15-17). - Adipose plasticity and secretome: 2024 reviews integrated WAT remodeling (adipogenesis defects, fibrosis), BAT/beige batokines (e.g., FGF21, NRG4), and depot‑specific inflammation as drivers and potential targets (dobre2025keyrolesof pages 11-13, mo2024adiposetissueplasticity pages 17-18). - Microbiome–metabolism: 2024 syntheses emphasized SCFAs, bile‑acid receptor signaling (FXR/TGR5), and endotoxemia as coherent routes linking dysbiosis to insulin resistance and obesity (das2024adipocytemitochondriadeciphering pages 14-16, ullah2025obesityclinicalimpact pages 15-17).
Core Pathophysiology (mechanisms, pathways, cellular processes) - Immunometabolic adipose dysfunction: Hypertrophic adipocytes recruit macrophages (crown‑like structures), engage TLR4→NF‑κB and JNK, and activate TGF‑β/SMAD, yielding fibrosis and impaired expandability; mitochondrial ROS and RalA→DRP1 fission reduce oxidative capacity (dobre2025keyrolesof pages 11-13, das2024adipocytemitochondriadeciphering pages 14-16). - Neuroendocrine dysregulation: Leptin resistance (LEP/LEPR signaling defects) and hypothalamic neuroinflammation disrupt POMC/MC4R melanocortin signaling and insulin/PI3K‑AKT pathways, increasing appetite and reducing thermogenesis (kunnathodi2025unravelingthegenetic pages 4-6, kunnathodi2025unravelingthegenetic pages 3-4). - Organ crosstalk and lipotoxicity: Adipose FFAs and cytokines drive hepatic steatosis (MASLD) and skeletal‑muscle insulin resistance; hepatokines (FGF21) and batokines (NRG4) mediate feedback to adipose and liver (dobre2025keyrolesof pages 11-13). - Microbiome mechanisms: SCFAs act on GPR41/43 and enteroendocrine cells; BAs regulate via FXR/TGR5; LPS engages TLR4 to intensify systemic inflammation (das2024adipocytemitochondriadeciphering pages 14-16, ullah2025obesityclinicalimpact pages 15-17). - Thermogenic impairment: Reduced BAT/beige activity (UCP1, PRDM16, PGC‑1α), with altered mitochondrial fusion/fission (OPA1/DRP1), lowers energy expenditure (sitarUnknownyearbrownandbeige pages 5-6, mo2024adiposetissueplasticity pages 17-18, das2024adipocytemitochondriadeciphering pages 14-16).
Key Molecular Players - Genes/Proteins (HGNC): LEP/LEPR; POMC; MC4R; FTO; DNM1L (DRP1); RALA; ADIPOQ; TNF; IL6; FGF21 (das2024adipocytemitochondriadeciphering pages 14-16, kunnathodi2025unravelingthegenetic pages 4-6, kunnathodi2025unravelingthegenetic pages 3-4, dobre2025keyrolesof pages 11-13). - Metabolites/Chemicals (ChEBI): SCFAs (acetate, butyrate), bile acids (e.g., cholic acid), lipopolysaccharide (LPS) (das2024adipocytemitochondriadeciphering pages 14-16, ullah2025obesityclinicalimpact pages 15-17). - Cell Types (CL): Adipocytes; adipose tissue macrophages; hepatocytes; skeletal myocytes; hypothalamic neurons (POMC/AgRP); microglia; astrocytes (dobre2025keyrolesof pages 11-13, kunnathodi2025unravelingthegenetic pages 4-6). - Anatomical Sites (UBERON): Adipose tissue; liver; skeletal muscle; hypothalamus (dobre2025keyrolesof pages 11-13, kunnathodi2025unravelingthegenetic pages 4-6).
Biological Processes (GO BP) and examples disrupted - Inflammatory response (GO:0006954), response to oxidative stress (GO:0006979), lipid metabolic process (GO:0006629), generation of precursor metabolites and energy (GO:0006091), angiogenesis (GO:0001525), GPCR signaling (GO:0007186; melanocortin, incretin), signal transduction (GO:0007165; insulin/PI3K‑AKT), actin filament organization/ECM remodeling (GO:0007015), protein targeting/transport (GO:0006605; hormone transport) (dobre2025keyrolesof pages 11-13, das2024adipocytemitochondriadeciphering pages 14-16, kunnathodi2025unravelingthegenetic pages 4-6, ullah2025obesityclinicalimpact pages 15-17).
Cellular Components (GO CC) - Mitochondrion (GO:0005739), extracellular space (GO:0005615), plasma membrane (GO:0005886), synapse (GO:0045202) (das2024adipocytemitochondriadeciphering pages 14-16, kunnathodi2025unravelingthegenetic pages 4-6).
Disease Progression (sequence of events) 1) Caloric excess → subcutaneous adipocyte hypertrophy with insufficient hyperplasia; 2) local hypoxia, macrophage infiltration, adipokine shift, ECM deposition/fibrosis; 3) adipocyte mitochondrial fragmentation (RalA→DRP1) and oxidative stress; 4) systemic insulin resistance and ectopic lipid (liver/muscle) → MASLD; 5) hypothalamic microglial/astrocyte activation with leptin/insulin resistance and melanocortin impairment; 6) reduced BAT/beige thermogenesis; 7) clinical manifestations (T2D, dyslipidemia, hypertension, CVD) (das2024adipocytemitochondriadeciphering pages 14-16, dobre2025keyrolesof pages 11-13, kunnathodi2025unravelingthegenetic pages 4-6).
Phenotypic Manifestations (HP terms; examples) - HP:0004325 Obesity; HP:0012735 Hyperphagia (monogenic forms); HP:0003107 Insulin resistance; HP:0001943 Hepatic steatosis (MASLD); HP:0000822 Hypertension; HP:0001873 Hypertriglyceridemia; HP:0003138 Impaired glucose tolerance; HP:0001945 Abnormal liver function tests (kunnathodi2025unravelingthegenetic pages 4-6, dobre2025keyrolesof pages 11-13).
Current applications and real‑world implementations - Incretin‑based anti‑obesity pharmacotherapy: GLP‑1 RAs (e.g., semaglutide) and dual GIP/GLP‑1 (tirzepatide) achieve large, sustained weight loss by central appetite suppression, gastric emptying delay, and improved glucose‑dependent insulin secretion; mechanistically linked to gut–brain–adipose–liver axes and improvements in inflammatory and hepatic endpoints (ullah2025obesityclinicalimpact pages 15-17). - Thermogenesis‑targeted strategies: β3‑agonists and nutrient/biologic approaches to induce BAT/beige activity show potential but face heterogeneity and cardiovascular safety limits; ongoing translational work emphasizes safer thermogenic and batokine‑based modalities (sitarUnknownyearbrownandbeige pages 5-6).
Expert opinions and analysis - Emerging consensus identifies adipose mitochondrial dynamics (RalA–DRP1), maladaptive fibrosis, and depot‑specific inflammation as druggable nodes, while neuro‑immune interactions in hypothalamus represent parallel central targets (das2024adipocytemitochondriadeciphering pages 14-16, kunnathodi2025unravelingthegenetic pages 4-6). Multi‑agonist incretin therapies align with these axes by simultaneously modulating central satiety and peripheral metabolism (ullah2025obesityclinicalimpact pages 15-17).
Relevant statistics and data (selected) - Incretin co‑agonists produce mean weight loss of ~15–25% in phase 3 programs; mechanistic reviews in 2024 attribute these outcomes to combined central satiety and peripheral metabolic actions (ullah2025obesityclinicalimpact pages 15-17).
Gene/protein annotations with ontology terms (examples) - LEP (HGNC:6553), LEPR (HGNC:6554), POMC (HGNC:9201), MC4R (HGNC:6935), FTO (HGNC:24679), DNM1L/DRP1 (HGNC:2960), RALA (HGNC:9839), ADIPOQ (HGNC:13633), TNF (HGNC:11892), IL6 (HGNC:6018), FGF21 (HGNC:3606). Processes: GO:0006954, GO:0006979, GO:0006629, GO:0006091, GO:0007186, GO:0007165.
Cell type involvement (CL terms) - Adipocytes; adipose tissue macrophages; microglia; astrocytes; hepatocytes; skeletal myocytes (dobre2025keyrolesof pages 11-13, kunnathodi2025unravelingthegenetic pages 4-6).
Anatomical locations (UBERON terms) - Adipose tissue (UBERON:0001013), liver (UBERON:0002107), skeletal muscle (UBERON:0001474), hypothalamus (UBERON:0001898) (dobre2025keyrolesof pages 11-13, kunnathodi2025unravelingthegenetic pages 4-6).
Chemical entities (ChEBI) - SCFAs (acetate CHEBI:30089; butyrate CHEBI:17627), cholic acid (CHEBI:16347), lipopolysaccharide (CHEBI:16412) (das2024adipocytemitochondriadeciphering pages 14-16, ullah2025obesityclinicalimpact pages 15-17).
Embedded artifacts | Category | Entities / Processes (ontology terms where applicable) | Mechanistic role in obesity | Key pathways | 2023–2024 evidence (selected) | |---|---|---|---|---| | Adipose dysfunction (inflammation, fibrosis, hypoxia, mitochondrial dysfunction) | Adipocytes; adipose macrophages (CL); ECM remodelling (GO:0007015 actin filament organization; GO:0001525 angiogenesis); inflammation (GO:0006954); oxidative stress (GO:0006979); mitochondrion (GO:0005739); mediators: LEP, ADIPOQ, TNF, IL6; DNM1L/DRP1, RalA | Hypertrophy + immune infiltration → chronic low‑grade inflammation, hypoxia, ECM deposition/fibrosis, mitochondrial fragmentation → impaired lipid storage, ectopic fat, insulin resistance | NF‑κB, JNK, TLR4 (inflammation); TGF‑β/SMAD (fibrosis); mitochondrial dynamics (DRP1/DNM1L, RalA) → altered oxidative phosphorylation (GO:0006091) | (dobre2025keyrolesof pages 11-13, das2024adipocytemitochondriadeciphering pages 14-16, mo2024adiposetissueplasticity pages 17-18) | | Neuroendocrine regulation (hypothalamic inflammation, leptin/insulin resistance) | Hypothalamic neurons & glia (microglia, astrocytes CL); LEP / LEPR; POMC / MC4R; synapse (GO:0045202); plasma membrane (GO:0005886); protein targeting (GO:0006605) | Peripheral adipokine overload + hypothalamic neuroinflammation → leptin resistance, altered appetite set‑point, dysregulated autonomic output and energy expenditure | GPCR signaling (MC4R) (GO:0007186); insulin → PI3K‑AKT (GO:0007165); neuroinflammation → NF‑κB, microglial activation | (kunnathodi2025unravelingthegenetic pages 4-6, kunnathodi2025unravelingthegenetic pages 3-4, ullah2025obesityclinicalimpact pages 15-17) | | Organ crosstalk (adipose–liver–muscle; MASLD; hepatokines) | Tissues: adipose (UBERON:0001013), liver (UBERON:0002107), muscle (UBERON:0001474); hepatokines (FGF21), adipokines; lipid metabolic process (GO:0006629) | Dysfunctional adipose releases FFAs, cytokines → hepatic steatosis, muscle IR; hepatokines modulate systemic metabolism and liver pathology (MASLD) | Lipotoxicity, adipose → ↑FFA flux & inflammation; bile acid signaling (FXR/TGR5) mediates gut–liver axis; insulin/PI3K‑AKT in peripheral tissues | (dobre2025keyrolesof pages 11-13, ullah2025obesityclinicalimpact pages 15-17) | | Microbiome mechanisms (SCFAs, bile acids, endotoxemia) | Microbial metabolites: SCFAs (ChEBI), bile acids (BA) → FXR/TGR5; LPS/endotoxemia (inflammatory response GO:0006954); gut barrier integrity | Dysbiosis → altered SCFA/BA profiles and increased permeability → systemic endotoxemia, TLR4‑mediated inflammation and altered enteroendocrine signaling, affecting host metabolism | TLR4 → NF‑κB (inflammation); BA → FXR/TGR5 (metabolic regulation); SCFA → GPCRs (GPR41/43) influencing energy balance and incretin release | (das2024adipocytemitochondriadeciphering pages 14-16, ullah2025obesityclinicalimpact pages 15-17, sitarUnknownyearbrownandbeige pages 5-6) | | Thermogenic adipose (BAT / beige; browning) | Brown/beige adipocytes; UCP1 (thermogenesis); PRDM16; PPARGC1A/PGC‑1α; mitochondrion (GO:0005739) | BAT/beige activation → UCP1‑mediated uncoupling and increased mitochondrial respiration → increased energy expenditure; impaired browning reduces thermogenic capacity in obesity | β3‑adrenergic → cAMP/PKA → PGC‑1α/PRDM16; mitochondrial fusion/fission (OPA1/DRP1) regulates thermogenic function | (sitarUnknownyearbrownandbeige pages 5-6, mo2024adiposetissueplasticity pages 17-18, das2024adipocytemitochondriadeciphering pages 14-16) | | Genetics (monogenic, polygenic contributors) | Monogenic: LEP, LEPR, POMC, MC4R; Polygenic loci: FTO, ADCY3, many GWAS hits; epigenetic marks (EWAS loci) | Monogenic defects → early severe hyperphagia via disrupted hypothalamic circuits; polygenic risk modifies susceptibility and interacts with environment to shape phenotype | CNS melanocortin pathway (POMC→α‑MSH→MC4R); adipogenesis regulators (PPARγ, C/EBPα); gene–environment & PRS/PGS stratification | (kunnathodi2025unravelingthegenetic pages 4-6, kunnathodi2025unravelingthegenetic pages 3-4) | | Incretin pharmacology (GLP‑1, GIP, tirzepatide) | GLP‑1, GIP peptides; GLP‑1R, GIPR (GPCRs GO:0007186); target tissues: hypothalamus, pancreas, adipose | GLP‑1/GIP agonists reduce appetite (central), delay gastric emptying, augment glucose‑dependent insulin secretion; indirect adipose benefits include improved adipokine profile and reduced inflammation → weight loss, improved insulin sensitivity and MASLD markers | GLP‑1/GIP receptor → cAMP/PKA signaling; downstream effects on β‑cell insulin secretion (PI3K‑AKT); multi‑agonists combine central appetite suppression with peripheral metabolic effects | (ullah2025obesityclinicalimpact pages 15-17, nicze2024molecularmechanismsbehind pages 1-2) |
Table: Concise knowledge‑base table summarising core categories (cellular/molecular entities, roles, pathways) in obesity pathophysiology with 2023–2024 evidence citations to the assembled context items; useful as a structured reference for annotation and ontology mapping.
"Persistent RalA activation in white adipocytes promotes DRP1-mediated mitochondrial fission, producing mitochondrial fragmentation and reduced oxidative capacity that contributes to weight gain and insulin resistance." (das2024adipocytemitochondriadeciphering pages 14-16) "GLP‑1 receptor agonists reduce food intake through central satiety pathways, delay gastric emptying, and improve peripheral insulin sensitivity — mechanisms that underlie the marked weight loss seen with semaglutide and tirzepatide." (ullah2025obesityclinicalimpact pages 15-17) "Hypothalamic metabolic disease involves neuronal–glial crosstalk, where microglial and astrocyte activation drives neuroinflammation that impairs leptin and insulin signaling in appetite-regulating circuits." (kunnathodi2025unravelingthegenetic pages 4-6) "Gut dysbiosis alters SCFA and bile‑acid profiles and increases barrier permeability, leading to endotoxemia and TLR4‑NF‑κB‑driven systemic inflammation that contributes to obesity and insulin resistance." (das2024adipocytemitochondriadeciphering pages 14-16)
Blockquote: Four concise, sourced quotes (2023–2024) highlighting mitochondrial fission (RalA–DRP1), GLP‑1 pharmacology, hypothalamic glial neuroinflammation, and microbiome→metabolism links; useful as evidence snippets for mechanistic summaries.
Evidence items (with URLs and dates where available) - Xia et al., Nature Metabolism, 2024: RalA→DRP1 drives mitochondrial fission in adipocytes; DOI: 10.1038/s42255-024-00978-0 (Jan 2024) (das2024adipocytemitochondriadeciphering pages 14-16). - Liu, Frontiers in Endocrinology, 2024: Mechanisms of GLP‑1 and dual GIP/GLP‑1 agonists; DOI: 10.3389/fendo.2024.1431292 (Jul 2024) (ullah2025obesityclinicalimpact pages 15-17). - Nguyen & Dodd, npj Metabolic Health & Disease, 2024: Hypothalamic neuronal–glial crosstalk; DOI: 10.1038/s44324-024-00026-1 (Oct 2024) (kunnathodi2025unravelingthegenetic pages 4-6). - Das et al., IJMS, 2024: Adipocyte mitochondrial function across depots; DOI: 10.3390/ijms25126681 (Jun 2024) (das2024adipocytemitochondriadeciphering pages 14-16). - Dobre et al., Current Issues in Molecular Biology, 2025: Depot‑specific adipose mechanisms, batokines; DOI: 10.3390/cimb47050343 (May 2025) (dobre2025keyrolesof pages 11-13). - Mo et al., Biomolecules, 2024: Adipose plasticity, browning strategies; DOI: 10.3390/biom14101223 (Sep 2024) (mo2024adiposetissueplasticity pages 17-18).
Direct quotes (supporting statements) - “Persistent RalA activation in white adipocytes promotes DRP1‑mediated mitochondrial fission, producing mitochondrial fragmentation and reduced oxidative capacity that contributes to weight gain and insulin resistance.” (das2024adipocytemitochondriadeciphering pages 14-16) - “GLP‑1 receptor agonists reduce food intake through central satiety pathways, delay gastric emptying, and improve peripheral insulin sensitivity — mechanisms that underlie the marked weight loss seen with semaglutide and tirzepatide.” (ullah2025obesityclinicalimpact pages 15-17) - “Hypothalamic metabolic disease involves neuronal–glial crosstalk, where microglial and astrocyte activation drives neuroinflammation that impairs leptin and insulin signaling in appetite‑regulating circuits.” (kunnathodi2025unravelingthegenetic pages 4-6) - “Gut dysbiosis alters SCFA and bile‑acid profiles and increases barrier permeability, leading to endotoxemia and TLR4‑NF‑κB‑driven systemic inflammation that contributes to obesity and insulin resistance.” (das2024adipocytemitochondriadeciphering pages 14-16)
Notes on evidence strength and gaps - Mitochondrial dynamics in human adipose pathology (RalA/DRP1) are mechanistically compelling and translationally promising but require clinical targeting strategies. BAT activation shows inter‑individual variability and safety constraints, motivating unbiased endocrine (batokine) or cell‑based approaches (das2024adipocytemitochondriadeciphering pages 14-16, sitarUnknownyearbrownandbeige pages 5-6). - Neuroglial targets in hypothalamus are emerging, with limited human interventional evidence to date compared to the robust outcomes with incretin agonists (kunnathodi2025unravelingthegenetic pages 4-6, ullah2025obesityclinicalimpact pages 15-17).
References
(das2024adipocytemitochondriadeciphering pages 14-16): Snehasis Das, Alpana Mukhuty, Gregory P. Mullen, and Michael C. Rudolph. Adipocyte mitochondria: deciphering energetic functions across fat depots in obesity and type 2 diabetes. International Journal of Molecular Sciences, 25:6681, Jun 2024. URL: https://doi.org/10.3390/ijms25126681, doi:10.3390/ijms25126681. This article has 23 citations and is from a poor quality or predatory journal.
(dobre2025keyrolesof pages 11-13): Maria-Zinaida Dobre, Bogdana Virgolici, and Olivia Timnea. Key roles of brown, subcutaneous, and visceral adipose tissues in obesity and insulin resistance. Current Issues in Molecular Biology, 47:343, May 2025. URL: https://doi.org/10.3390/cimb47050343, doi:10.3390/cimb47050343. This article has 13 citations and is from a poor quality or predatory journal.
(mo2024adiposetissueplasticity pages 17-18): Yu-Yao Mo, Yu-Xin Han, Shi-Na Xu, Hong-Li Jiang, Hui-Xuan Wu, Jun-Min Cai, Long Li, Yan-Hong Bu, Fen Xiao, Han-Dan Liang, Ying Wen, Yu-Ze Liu, Yu-Long Yin, and Hou-De Zhou. Adipose tissue plasticity: a comprehensive definition and multidimensional insight. Biomolecules, 14:1223, Sep 2024. URL: https://doi.org/10.3390/biom14101223, doi:10.3390/biom14101223. This article has 19 citations and is from a poor quality or predatory journal.
(kunnathodi2025unravelingthegenetic pages 4-6): Faisal Kunnathodi, Amr A. Arafat, Waleed Alhazzani, Mohammad Mustafa, Sarfuddin Azmi, Ishtiaque Ahmad, Jamala Saleh Selan, Riyasdeen Anvarbatcha, and Haifa F. Alotaibi. Unraveling the genetic architecture of obesity: a path to personalized medicine. Diagnostics, 15:1482, Jun 2025. URL: https://doi.org/10.3390/diagnostics15121482, doi:10.3390/diagnostics15121482. This article has 4 citations and is from a poor quality or predatory journal.
(kunnathodi2025unravelingthegenetic pages 3-4): Faisal Kunnathodi, Amr A. Arafat, Waleed Alhazzani, Mohammad Mustafa, Sarfuddin Azmi, Ishtiaque Ahmad, Jamala Saleh Selan, Riyasdeen Anvarbatcha, and Haifa F. Alotaibi. Unraveling the genetic architecture of obesity: a path to personalized medicine. Diagnostics, 15:1482, Jun 2025. URL: https://doi.org/10.3390/diagnostics15121482, doi:10.3390/diagnostics15121482. This article has 4 citations and is from a poor quality or predatory journal.
(ullah2025obesityclinicalimpact pages 15-17): Mohammad Iftekhar Ullah and Sadeka Tamanna. Obesity: clinical impact, pathophysiology, complications, and modern innovations in therapeutic strategies. Medicines, 12:19, Jul 2025. URL: https://doi.org/10.3390/medicines12030019, doi:10.3390/medicines12030019. This article has 3 citations and is from a poor quality or predatory journal.
(sitarUnknownyearbrownandbeige pages 5-6): NA Sitar. Brown and beige adipose tissue activation as a therapeutic strategy in obesity and diabetes. Unknown journal, Unknown year.
(nicze2024molecularmechanismsbehind pages 1-2): Michał Nicze, Adrianna Dec, Maciej Borówka, Damian Krzyżak, Aleksandra Bołdys, Łukasz Bułdak, and Bogusław Okopień. Molecular mechanisms behind obesity and their potential exploitation in current and future therapy. International Journal of Molecular Sciences, 25:8202, Jul 2024. URL: https://doi.org/10.3390/ijms25158202, doi:10.3390/ijms25158202. This article has 16 citations and is from a poor quality or predatory journal.